

Liquid biopsy assay, 7/16

July 2016—Foundation Medicine has launched an analytically validated and accurate blood-based circulating tumor DNA assay that provides patients and oncologists with a new option for comprehensive genomic profiling when a tissue biopsy is not feasible or when tissue is not available. The Foundation Assay for Circulating Tumor DNA, or FoundationACT, can identify clinically relevant genomic alterations and delivers this comprehensive molecular information in a concise report that matches the findings with potentially relevant targeted therapies and clinical trials.

FoundationACT, which was launched to Foundation Medicine's pharmaceutical partners for research use in December 2015, interrogates all clinically relevant alterations across 62 genes and fusions across six genes, and it has been optimized for sensitivity and specificity of all classes of molecular alterations, including base substitutions, insertions and deletions, focal amplifications, and gene fusions.

[**Foundation Medicine**](#), 617-418-2200